TY - JOUR
T1 - Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study
AU - Visser, Nicole C.M.
AU - van der Putten, Louis J.M.
AU - van Egerschot, Alex
AU - Van de Vijver, Koen K.
AU - Santacana, Maria
AU - Bronsert, Peter
AU - Hirschfeld, Marc
AU - Colas, Eva
AU - Gil-Moreno, Antonio
AU - Garcia, Angel
AU - Mancebo, Gemma
AU - Alameda, Francesc
AU - Krakstad, Camilla
AU - Tangen, Ingvild L.
AU - Huvila, Jutta
AU - Schrauwen, Stefanie
AU - Koskas, Martin
AU - Walker, Francine
AU - Weinberger, Vit
AU - Minar, Lubos
AU - Hausnerova, Jitka
AU - Snijders, Marc P.L.M.
AU - van den Berg-van Erp, Saskia
AU - Matias-Guiu, Xavier
AU - Trovik, Jone
AU - Amant, Frédéric
AU - Massuger, Leon F.A.G.
AU - Bulten, Johan
AU - Pijnenborg, Johanna M.A.
N1 - Copyright © 2019 Elsevier Inc. All rights reserved.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - © 2019 Elsevier Inc. Discrimination between low- and high-grade endometrial carcinomas (ECs) is clinically relevant but can be challenging for pathologists, with moderate interobserver agreement. Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is an oncofoetal protein that is associated with nonendometrioid endometrial carcinomas but has been limited studied in endometrioid carcinomas. The aim of this study is to investigate the diagnostic and prognostic value of IMP3 in the discrimination between low- and high-grade ECs and its added value to L1CAM. IMP3 and L1CAM expression was assessed in tumors from 378 patients treated for EC at 1 of 9 participating European Network for Individualised Treatment of Endometrial Cancer centers. IMP3 was expressed in 24.6% of the tumors. In general, IMP3 was more homogeneously expressed than L1CAM. IMP3 expression was significantly associated with advanced stage, nonendometrioid histology, grade 3 tumors, deep myometrial invasion, lymphovascular space invasion, distant recurrences, overall mortality, and disease-related mortality. Simultaneous absence of IMP3 and L1CAM expression showed the highest accuracy for identifying low-grade carcinomas (area under the curve 0.766), whereas simultaneous expression of IMP3 and L1CAM was strongly associated with high-grade carcinomas (odds ratio 19.7; 95% confidence interval 9.2-42.2). Even within endometrioid carcinomas, this combination remained superior to IMP3 and L1CAM alone (odds ratio 8.6; 95% confidence interval 3.4-21.9). In conclusion, IMP3 has good diagnostic value and together with L1CAM represents the optimal combination of diagnostic markers for discrimination between low- and high-grade ECs compared to IMP3 and L1CAM alone. Because of the homogenous expression of IMP3, this marker might be valuable in preoperative biopsies when compared to the more patchy L1CAM expression.
AB - © 2019 Elsevier Inc. Discrimination between low- and high-grade endometrial carcinomas (ECs) is clinically relevant but can be challenging for pathologists, with moderate interobserver agreement. Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is an oncofoetal protein that is associated with nonendometrioid endometrial carcinomas but has been limited studied in endometrioid carcinomas. The aim of this study is to investigate the diagnostic and prognostic value of IMP3 in the discrimination between low- and high-grade ECs and its added value to L1CAM. IMP3 and L1CAM expression was assessed in tumors from 378 patients treated for EC at 1 of 9 participating European Network for Individualised Treatment of Endometrial Cancer centers. IMP3 was expressed in 24.6% of the tumors. In general, IMP3 was more homogeneously expressed than L1CAM. IMP3 expression was significantly associated with advanced stage, nonendometrioid histology, grade 3 tumors, deep myometrial invasion, lymphovascular space invasion, distant recurrences, overall mortality, and disease-related mortality. Simultaneous absence of IMP3 and L1CAM expression showed the highest accuracy for identifying low-grade carcinomas (area under the curve 0.766), whereas simultaneous expression of IMP3 and L1CAM was strongly associated with high-grade carcinomas (odds ratio 19.7; 95% confidence interval 9.2-42.2). Even within endometrioid carcinomas, this combination remained superior to IMP3 and L1CAM alone (odds ratio 8.6; 95% confidence interval 3.4-21.9). In conclusion, IMP3 has good diagnostic value and together with L1CAM represents the optimal combination of diagnostic markers for discrimination between low- and high-grade ECs compared to IMP3 and L1CAM alone. Because of the homogenous expression of IMP3, this marker might be valuable in preoperative biopsies when compared to the more patchy L1CAM expression.
KW - Diagnostic biomarker
KW - Endometrial carcinoma
KW - IMP3
KW - L1CAM
KW - Prognostic biomarker
UR - http://www.mendeley.com/research/addition-imp3-l1cam-discrimination-between-low-highgrade-endometrial-carcinomas-european-network-ind
U2 - 10.1016/j.humpath.2019.04.014
DO - 10.1016/j.humpath.2019.04.014
M3 - Article
C2 - 31054899
SN - 0046-8177
VL - 89
SP - 90
EP - 98
JO - Human Pathology
JF - Human Pathology
ER -
